Recent progress in the clinical development of thromboxane A₂ receptor antagonists

References

• HAMBERG M, SVENSSON J, SAMUELSSON B: Thrombox-anes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA (1975) 72:2994–98.
   PubMed Web of Science ®Google Scholar
• HALUSHKA PV, MAIS DE: Basic and clinical pharmacol-ogy of thromboxane A2. Drugs of Today (1989) 25:383–93.
   Google Scholar
• SMITH EF: Thromboxane A2 in cardiovascular and renal disorders: is there a defined role for thromboxane receptor antagonists or thromboxane synthase inhibi-tors? Eicosanoids (1989) 2:199–212.
   PubMedGoogle Scholar
• HALL SE: Thromboxane A2 receptor antagonists. Med. Res. Rev. (1991) 11:503–79.
   PubMed Web of Science ®Google Scholar
• An excellent comprehensive review of pre-clinical and clinical studies; also includes combined TP antagonist/synthase inhibitors.
   Google Scholar
• PATRONO C: Thromboxane synthesis inhibitors andreceptor antagonists. Thromb. Res. (1990) 11(Suppl.):15–23.
   Google Scholar
• FIDDLER GI, LUMLEY P: Preliminary clinical studies with thromboxane synthase inhibitors and thromboxanereceptor blockers. A review. Circulation (1990) 81(Suppl.
   Google Scholar
• An excellent review covering pre-1990 clinical studies of TP antago-nists and synthase inhibitors.
   Google Scholar
• AA-2414 Drugs Future (1990) 15:783–5.
   Google Scholar
• ASHIDA Y, MATSUMOTO T, KURIKI H, SHIRAISHI M, KATOK, TERAO S: A novel anti-asthmatic- quinane derivative, AA-2414 with a potent antagonistic activity against a variety of spasmogenic prostanoids. Prostaglandins (1989) 38:91–112.
   PubMedGoogle Scholar
• NISHIKAWA K, ASHIDA Y, TERASHITA Z, KURIKI H, NAKA-MURA N, SHIMIZU M: AA-2414- a novel and long acting thromboxane (tx) A2 receptor antagonist. Eur. J. Clin. Pharmacol. (1992) 33(Suppl.)A298.
   Google Scholar
• ORCHARD MA, WARD C, LOCKE CS, RINGHAM GL: Inves-tigation of oral Abbott-73011 (Takeda AA-2414) on plate-let function in normal volunteers. Br. J. Clin. Pharmacol. (1992) 33:541P–542P.
   Google Scholar
• HUSSEIN Z, ORCHARD MA, RINGHAM GL, GRANNEMAN GR, LOCKE CS: Assessment of pharmacokinetic (pk)/pharrnacodynamic (pd) relationship for A-73011/AA-2414. Pharm. Res. (1992) 92(Suppl.):S304.
   Google Scholar
• FUJIMURA M, SAKAMOTO S, SAITO M, MIYAKE Y, MAT-SLTDA T: Effect of a thromboxane A2 receptor antagonist (AA-2414) on bronchial hyperresponsiveness to methacholine in subjects with asthma. J. Allergy Clin. Immunol. (1991) 87\(Part 1):23–7.
   Google Scholar
• HADA S, HASHIZUME M, NISHII S, YOSHIOKA F, YASUNGA K: Study on the inhibitory effect of AA-2414 on platelet aggregation and its clinical effect in asthmatic patients. Aretugi (1993) 42:18–25.
   Google Scholar
• MANNHOLD R: BM-13177. Drugs Future (1984) 9:804–6.
   Google Scholar
• HACKER RW, TORKA M, YUEKSELTAN I, POHLMANN V, MEIER P, ZIMMERMAN T, El 11 H: Reduction of the vein graft occlusion rate after coronary artery bypass sur-gery by treatment with a thromboxane receptor antago-nist. Z. Kardiol. (1989) 78\(Suppl. 3):48–9.
   Google Scholar
• LUDWIG P, HOEFLING B, STAEBLEIN A, VON ARNIM T: Thromboxan- antagonist BM 13.177 compared to aspi-rin in preventing restenosis after ptca. Eur.HeartJ. (1987) 8\(Suppl. 2):225.
   Google Scholar
• FINCI L, HOEFLING B, LUDWIG B, BULTITA M, STEFFEN-INO G, ETTI H, MEIER B: Sulotroban during and after coronary angioplasty. A double- blind, placebo-control-led study. Z. Kardiol. (1989) 78 (Suppl. 3):50–4.
   Google Scholar
• SAVAGE MP, GOLDBERG S, MACDONALD RG, BASS TA, MARGOLIS JR, WHITWORTH FIB, TAUSSIG AS, VETROVEC G, COWLEY M, BOVE AA, KLEAVELAND P, HIRSHFELD JW, HILL JA, GILMORE P, PEPINE CJ: Multi-hospital Eastern Atlantic restenosis trial II: a placebo-controlled trial of thromboxane blockade in the prevention of restenosis following coronary angioplasty. Am. Heart J. (1991) 122:1239–44.
   PubMed Web of Science ®Google Scholar
• Design of a definitive trial on restenosis in PTCA.
   Google Scholar
• BOVE A, SAVAGE M, DEUTSCH E, MACDONALD R, BASS T, VETROVEC G, WHITWORTH H, COWLEY M, GOLDBERG S, MARGOLIS J, HILL J, HIRSHFELD J, GRANETT J, PEPINE C: Effects of selective and non-selective thromboxane A2 blockade on restenosis after ptca: m-heart IL J. Am. Coll. Cardiol. (1992) 19(Suppl. A):259A.
   Google Scholar
• Preliminary results of a large, definitive trial on restenosis in PTCA.
   Google Scholar
• LONSDALE RJ, HEPTINSTALL S, BERRIDGE DC, WENHAM PW, MAKIN GS, HOPKINSON BR: Platelet function during peripheral arterial thrombolysis with streptokinase and sulotroban. 7bromb. Haemeostasis (1991) 65:1189.
   Web of Science ®Google Scholar
• LONSDALE RJ, HEPTINSTALL S, WESTBY JC, BERRIDGE DC, WENHAM PW, HOPKINSON BR, MAKIN GS: A study of the use of the thromboxane A2 antagonist, sulotroban, in combination with streptokinase for local thrombolysis In patients with recent peripheral arterial occlusions: clinical effects, platelet function and fibrinolytic pa-rameters. Thromb. Haemeostasis (1993) 69:103–11.
   PubMed Web of Science ®Google Scholar
• GRANETT JR, PARCHMAN LG, SINGH 10, BOVE AA: Effect of a thromboxane receptor antagonist (sulotroban) versus aspirin when combined with streptokinase for acute myocardial infarction. Eur. Heart J. (199:) 13(Suppl.):450.
   Google Scholar
• LUMLEY P, FINCH H, COLLINGTON EWC, HUMPHREY PPA: Vapiprost hydrochlorkle. Drugs Future (1990) 15:1087–92.
   Google Scholar
• HUMPHREY PPA, HALLET P, HORNBY EJ, WALLIS CJ, COLLINGTON EW, LUMLEY P: Pathophysiological ac-tions of thromboxane A2 and their pharmacological antagonism by thromboxane receptor blockade with GR32191. Circulation (1990) 81(Suppl. I):1-42 to 1–52.
   Google Scholar
• A review of pre-clinical studies.
   Google Scholar
• THOMAS M, LUMLEY P: Preliminary assessment of anovel thromboxane A2 receptor-blocking drug, GR32191, in healthy subjects. Circulation (1990) 81\(Suppl. 1):1–53 to 1–58.
   Google Scholar
• UEMATSU T, NAGASHIMA S, MIZUNO A, HIRANO K, NAKASHIMA M: Pharmacokinetic and pharmacody-namic profiles of vapiprost, a selective, long-lasting thromboxane receptor antagonist, after single and mul-tiple oral administration to healthy volunteers. J. Clin. Pharmacol. (1991) 31:815–22.
   PubMed Web of Science ®Google Scholar
• HOGG KJ, GEMMILL JD, LIFSON K, RAE AP, DUNN FG,HILLIS WS: Thromboxane A2 receptor antagonist (61132191) is as effective as anticoagulants in maintain-ing vessel patency post thrombolytic therapy. Circula-tion (1989) 80\(Suppl. 11):II–50.
   Google Scholar
• SURRUYS PW, RUTSCH W, HEYNDR1CKS GR, DANCHIN N, MAST EG, WIJNS W, RENSING BJ, VOS J, STIBBE J: Preven-tion of restenosis after percutaneous transluminal coronary angioplasty with thromboxane A2- receptor blockade. Circulation (1991) 81568–80.
   Google Scholar
• Definitive study on restenosis and clinical course in PTCA.
   Google Scholar
• FELDMAN RL, BENGTSON JR, PRYOR DB, ZIMMERMAN MB: The GRASP study:use of a thromboxane A2 receptor blocker to reduce adverse clinical events after coronary angioplasty. J. Am. Coll. Cardiol. (1992) 19(Suppl. A):259A.
   Google Scholar
• Preliminary results of a large study on effects on adverse clinical events in PTCA.
   Google Scholar
• BEASLEY RCW, FEATHERSTONE RL, CHURCH MK, RAF-FERTY P, VARLEY JG, HARRIS A, ROBINSON C, HOLGATE: Effect of a thromboxane receptor antagonist on P6132 and allergen-induced bronchoconstriction. J. Appl. Physiol. (1989) 66:1685–93.
   PubMed Web of Science ®Google Scholar
• STENTON SC, YOUNG CA, HARRIS A, PALMER JBD, HEN-DRICK DJ, WALTERS EH: The effect of GR32191 (a throm-boxane receptor antagonist) on airway responsiveness In asthma. Pulm. Pharmacol. (1992) 53:199–202.
   Google Scholar
• FINNERTY JP, I WENTYMAN OP, HARRIS A, PALMER JBD,HOLGATE ST: Effect of GR32191, a potent thromboxane receptor antagonist, on exercise induced bronchocon-striction in asthma. Thorax (1991) 46:190–2.
   PubMed Web of Science ®Google Scholar
• SIENTON SC, WARD C, DUDDRIDGE M, HARRIS A, PAL-MER JBD, HENDRICK DJ, WALTERS EH: The actions of GR32191b, a thromboxane receptor antagonist, on the effects of inhaled PAF on human airways. Clin. Exp. Allergy (1990) 20:311–7.
   PubMed Web of Science ®Google Scholar
• KEITTELMANN S, SVENDSEN UG, SJOGREN P, FAUR-SCHOU P, PEDERSEN B, DAHL R, JOHNSEN C, MADSEN F, PALMER JBD: The effect of a thromboxane receptor receptor antagonist (GR32191b) in moderate to severe asthma. Clin. Exp. Allergy (1990) 20:96.
   Google Scholar
• COLEMAN RA: 6R32191 and the role of thromboxane A2 in asthma- preclinical and clinical findings. Agents Ac-tions Suppl. (1991) 34:211–20.
   PubMedGoogle Scholar
• A review of pre-clinical and clinical results in asthma.
   Google Scholar
• LYONS D, FOWLER G, PETRIE JC, WEBSTER J: The haemodynamic effects of GR 32191, a thromboxane A2 receptor antagonist, in patients with renal artery stenosis. Br. J. Clin. Pharmacol. (1993) 36:271–3.
   PubMed Web of Science ®Google Scholar
• Study showing no effect on hypertension in patients with RAS.
   Google Scholar
• PTACHCINCKI RJ, LOPATIN W, FINN W, WOMBOLT DG, BENNETT WM, ICLEIN JB, COFFMAN TM: Evaluation of the Interaction between 6R32191 and cyclosporine follow-ing renal transplantation. Pharmacotherapy(1989) 9:193.
   Google Scholar
• MOBB GE, WHITING PH, FEEHALLY J, WITCH PS, BELL PRF: The effect of the thromboxane receptor antagonist GR32191b on cyclosporine- induced nephrotoxkity. Transplant. Proc. (1991) 23:1241–3.
   PubMed Web of Science ®Google Scholar
• Study showing no benefit in cyclosporine-induced nephrotoxity.
   Google Scholar
• PERZBORN E, BOBERG M, BUEHNER K, BOESHAGEN H, FIEDLER VB, GARDINER PJ, MUELLER U, NORMAN P, RTITER W, ROSENTRETER U, SEUTER F, WEBER H: Bay u 3405. Drugs Future (1991) 16:701–5.
   Google Scholar
• RITTER W, WEBER H, KUHLMANN J: Single and multiple dose pharmacokinetics of the thromboxane A2 antago-nist BAY u 3405.J. Chn. Pharmacol. (1990) 30:849.
   Google Scholar
• WEBER H, RITTER W, PERZBORNM E, KUHLMANN J: Tol-erability and pharmacodynamic effects of the throm-boxane A2 antagonist BAY u 3405 in healthy volunteers. J. Clin. Pharmacol. (1990) 30:849.
   Google Scholar
• BARDIN PG, JOHNSTON SL, SMITH SJOUBERT JR, RITTER W, HOWARTH PH, HOLGATE ST: The effect of thrombox-ane receptor antagonism on P61)2-induced broncho-constriction and nasal blockage. Am. Rev. Respir. Dis. (1992) 145\(Part 2):A291.
   Google Scholar
• JOHNSTON SL, SMITH S, HARRISON J, RITTER W, HOWARTH PH: The effect of BAY u 3405, a thromboxane receptor antagonist, on prost2g1and1n D2-induced na- sal blockage. J. Allergy an. Immunol. (1993) 91:903-9. Study showing lack of efficacy in allergic rhinitis.
   Google Scholar
• JOHNSON SL, BARDIN PG, RITTER W, JOUBERT JR, HOL-GATE ST: The effect of BAY u 3405, a thromboxane receptor antagonist, on prostaglandin (PG) and hista-mine (H) bronchial challenge and correlation of effi-cacy with plasma levels. Eur. Resp. J. (1991) 4 (SuppL 14):264s–265s.
   Google Scholar
• JOHNSTON SL, BARDIN PG, HARRISON J, RITTER W, JOUBERT JR, HOLGATE ST: The effects of an oral throm-boxane TP receptor antagonist BAY u 3405, on pro-staglandin 132- and histamine-induced bronchoconstriction in asthma, and relationship to plasma drug concentrations. Br.J. Clin . Pharmacol. (1992) 34:402–8.
   PubMed Web of Science ®Google Scholar
• MAGNUSSEN H, BOERGER S, TEMPLIN K, BAUNACK AR: Effects of a thromboxane-receptor antagonist, BAY u 3405, on prostaglandin D2- and exercise-induced bron-choconstriction. Eur. Resp. (1991) 4\(Suppl. 14):264s.
   Google Scholar
• MAGNUSSEN H, BOERGER S, TEMPLIN K, BAUNACK AR: Effects of a thromboxane-receptor antagonist, BAY u 3405, on prostaglandin 1)2-and exercise-induced bron-choconstriction. J. Allergy Clin. Immunol. (1992) 89:1119–26.
   PubMed Web of Science ®Google Scholar
• Study showing effectiveness in PGD2-induced bronchoconstriction.
   Google Scholar
• R1AMBAU V, DE CASTELLARNAU C, GARCIA C, GONZALEZ O, ALBORS M, VIVER E: Effect of a new thrornboxane antagonist, BAY u 3405, on platelet function in patients with peripheral vascular disease. Thromb. Haemeastasis (1993) 69:1321.
   Web of Science ®Google Scholar
• BELLUCCI S, ICEDRA A, MOLHO-SABATIER P, ANDREAS-SIAN B, TOBFIFM G: In vivo inhibition of platelet aggre-gation in patients with severe limb arteriopathy treated with BAY u 3405, a specific TxA2 receptor antagonist. Thromb. Haemeostasfs (1993) 69:639_
   Google Scholar
• PIETERS H, ROODT JP, BADENHORST PN, VAN WYK V, SCHALL R, LOETTER MG, HUNDT HICL, NEL CJC: An-tithrombotic activity of BAY u 3405, a thromboxane A2-antagonist, in patients with dacron aortic grafts: a random controlled clinical trial. Tbromb. Haemostasis (1993) 70:903–8.
   PubMed Web of Science ®Google Scholar
• Study showing efficacy as an antithrombotic in mature aortic grafts.
   Google Scholar
• BREWSTER AG, BROWN GR, FOUBISTER AJ, JESSUP R, SMITHERS MJ: The synthesis of a novel thromboxane receptor antagonist 4(z)-6-(2-o-chloropheny1-4-o-hy-droxypheny1-1,3-dioxan-cis-5-y1) hexenoic acid ICI 192605. Prostaglandins (1988) 36:173–8.
   PubMedGoogle Scholar
• JESSUP CLJESSUP R, WAYNE M: The effect of ICI 192,605, a selective thromboxane A2 receptor antagonist, on platelets. Br. J. PharrnacoL (1988) 95(Suppl.):676P.
   Google Scholar
• JESSUP CL, JESSUP R, STARK RD, WILLIAMS C: ICI 192605; a potent, selective thromboxane receptor antagonist is orally active in man. Br.J. Clin. Pharmacol. (1989) 27:710P.
   Web of Science ®Google Scholar
• HORN EH, COOPER J, HARDY E, RUBIN PC: Effects on platelet behaviour and bleeding time of the thrombox-ane receptor antagonist ICI- 192605 in healthy subjects. Br. J. Haematol. (1990) 76\(Suppl. 1):12.
   Google Scholar
• FRENCH SB, PRASAD R, LEESE P, YEH C, THYRUM PT: Pharmacodynamics of a substituted 1,3-dioxane (ICI 192,605), a novel thromboxane A2 receptor antagonist Clin. Pharmacol. Ther. (1991) 49:141.
   Web of Science ®Google Scholar
• LAU CS, MCLAREN M, BANCROFT A, KHAN F, BELCH BF: A study to investigate the effects of ICI-192,605, a throm-lboxane Al receptor antagonist, in patients with secon-dary Baynaud's phenomenon. Br.J. Rbeumatol. (1990) 29 (Suppl. 2):1.
   Google Scholar
• LAU CS, 1(1-IAN F, MCLAREN, BANCROFT A, WALKER M, BELCH JJ: The effects of thromboxane receptor blockade on platelet aggregation and digital skin blood flow in patients with secondary Raynaud's syndrome. Rheuma-tol. Int. (1991) 11:163–8.
   PubMed Web of Science ®Google Scholar
• SINGH V, WISNIEWKI AFZ, COOPERS, HIGGINS, TATTERS-FIELD: Effect of ICI 192,605 a thromboxane receptor antagonist on the response to inhaled antigen in asthma. Am. Rev. Respir. Dir. (1990) 141\(Part 2):A838.
   Google Scholar
• WILKENS H, WILKENS JH, MUELLE I, BOEVERS J, SUCHY MT, FROLICH JC: Effect of a thromboxane receptor antagonist, ICI 192,605, on exercise-induced asthma in man. Eur. Resp. J. (1990) 3\(Suppl. 10):319S.
   Google Scholar
• DUBE GP, KURTZ WL, MA'S DE, BRUNE KA, RINKEMA LE, JAKUBOWSKI JA: In vitro profile of a novel thrombox-ane Al antagonist in platelets and arteries. Circulation (1989) 80(Suppl.
   Google Scholar
• NARISADA M, OHTANI M, WATANABE F, UCHIDA K, ARITA H, DOTEUCHI M, UEDA M, HANASAKI K, ICAKUSHI H, OTANI K, HARA 5, NAKAJIMA M: Synthesis and in vitro effects on platelets and vascular smooth muscle of S-145, a novel thromboxane receptor antagonist Adv. Prostaglandin Thromboxane Leukotriene Res. (1989) 19:659–
   PubMedGoogle Scholar
• JYOYAMA H, HORI Y, HATAKEYAMA H, ASANUMA F, KUROSAWA: Antithrombotic action of the orally avail-able thromboxane Al receptor antagonist S-1452 (d-S-145 Ca) in rodents. Drug Dev. Res. (1993) 30:62–71.
   Web of Science ®Google Scholar
• JYOYAMA H, KUROSAWA: Preventive effect of the thromboxane Al receptor antagonist S-1452 (d-S-145 Ca) on arachidonate-induced sudden death and cere-bral infarction in rabbits. Drug Dev. Res, (1993) 30:72–77.
   Web of Science ®Google Scholar
• ASANUMA F, JYOYAMA H, KUROSAWA: Transient agonist-like action of the thromboxane Al receptor antagonist S-1452 (d-S-145 Ca) and its reduction by gradual injection or oral administration. Drug Dev. Res. (1993) 30:78–82.
   Web of Science ®Google Scholar
• FUJIMURA, ICUMAGAI K, OHASHI K, EBIHARA: Effect oftreatment at night with 5-1452, a thromboxane Al receptor antagonist, on the morning rise in platelet aggregation. Eur. J. Clin. Pharmacol. (1992) 43:501–5.
   PubMed Web of Science ®Google Scholar
• ON0-3708. Drugs Future (1987) 12:446–9.
   Google Scholar
• TANEYAMA C, GOTO H: ONO 3708: anew thromboxane Al receptor antagonist Cardiovascular Drug Rev. (1990) 8:339-49.
   Google Scholar
• LAFFI G, MARRA F, CARLONI V, AZZENA G, DE FE0 ML,PINZANI M, TOSTI-GUERRA C, GENTTLINI P: Thrombox-ane-receptor blockade increases water diuresis in cir-rhotic patients with ascites. Gastroenterology (1992) 103:1017–21.
   PubMedGoogle Scholar
• YOSHIOKA M, WAICAMATSU M, KURO M, OKUMURA F: The effects of thromboxane receptor antagonist on hemodynamic responses after neutralization of hepa-rin by protamine. Masui (1991) 40:918–22.
   PubMedGoogle Scholar
• Study showing efficacy in reducing protamine-induced hyperten-sion.
   Google Scholar
• PATSCHEICE H, STEGMEIER K, HORNBERGER W, STAIGER C, NEUGEBAUER G: Inhibition of platelet activation by the novel thromboxane receptor antagonist BM 13.505. Tbromb. Haemastasis (1987) 58:182.
   Web of Science ®Google Scholar
• TIBES U, GERSTHEIMER F, LUECICER P, UEBIS U: Pharma-cokinetics and pharmacodynamics of the TxA2 recep-tor blocker daltroban after multiple po dosing. Thromb. Haemostasis (1989) 62:410.
   Web of Science ®Google Scholar
• MISER RN, WHITE RE, OGLETREE: Ifetroban Sodium. Drugs Future (1994) 19:107–111.
   Google Scholar
• Summary of synthesis, early pre-clinical pharmacology and metabo-lism.
   Google Scholar
• MISER RN, BROWN BR, SHER PM, PATEL MM, HALL SE, HAN WC, BARRISH JC, FLOYD DM, SPRAGUE PW, MORRI-SON RA, RIDGEWELL RE, WHITE RE, DIDONATO GC, HARRIS DN, HEDBERG A, SCHUMACHER WA, WEBB ML, OGLETREE ML: Thromboxane receptor antagonist EMS-180291: a new pre-clinicallead. (1992) BfoMed. Chem. Lett 2:73–6.
   Google Scholar
• MISER RN, BROWN BR, SUER PM, PATEL MM, HALL SE, HAN WC, BARRISH JC, KOCY O, HARRIS DN, GOLDEN-BERG HJ, MICHEL I, SCHUMACHER WA, WEBB ML, MON-SHIZADEGAN H, OGLETREE ML: Interphenylene 7-oxabicyclo[2.2.11heptane oxazoles. Highly potent, se-lective and long-acting thromboxane Al receptor an-tagonists. J. Med. Chem. (1993) 36:1401–17.
   Google Scholar
• OGLETREE ML, HARRIS DN, SCHUMACHER WA, WEBB ML, MISER RN: Pharmacological profile of BMS 180,291: a potent, long-acting, orally active thromboxane A2/pro-staglandin endoperoxide receptor antagonist J. Phar-macoL Exp. Ther. (1993) 264:570–8.
   PubMed Web of Science ®Google Scholar
• Summary of early pre-clinical pharmacology.
   Google Scholar
• SCHUMACHER WA, STEINBACHER TE, YOUSSEF S, OGLE- TREE ML: Antiplatelet activity of the long-acting throm-boxane receptor antagonist BMS 180,291 in monkeys. Prostaglandins (1992) 44:389–97.
   PubMedGoogle Scholar
• KOSLO RJ, FARINA V, OGLETREE ML, ABERG G: Gastro-protective effect of BMS 180,291: a new thromboxane receptor antagonist. Gastroenterology (1992) 102:A102.
   PubMedGoogle Scholar
• GOMOLL AW, GROVER GJ, OGLETREE ML: Myocardial salvage efficacy of the novel thromboxane A2 / pro-staglandin endoperoxide antagonist, BMS 180,291, in the ferret and dog. Submitted.
   Google Scholar
• Study showing efficacy in animal models of ischaemia.
   Google Scholar
• GROVER GJ, SCHUMACHER WA, OGLETREE ML: The thromboxane receptor antagonist HMS-180291, but not aspirin reduces the severity of pacing-induced ischemia In dogs. Submitted.
   Google Scholar
• Study showing benefit over aspirin in dog model of ischaemia.
   Google Scholar
• 'WEBB ML, LIU ECK, MONSHIZADEGAN H, HEDBERG A, MISRA RN, GOLDENBERG H, HARRIS DN: Binding and function of a potent new thromboxane receptor an-tagonist, BMS 180,291, in human platelets./ Pharmacol. Exp. Ther. (1993) 264:1387–94.
   Google Scholar
• KW-3635. Drugs Future (1992) 17:782–7.
   Google Scholar
• KARASAWA A, KAWAKAGE M, SHIRAICURA S, HIGO K, KUBO K, OHSHIMA E, OBASE H: Antiplatekt effects of the novel thromboxane A2 receptor antagonist sodium (e)-11-[2-(5,6-dimethyl-1-benzimidazoly1)- ethyliclene]-6,11-dihydrodlbenz[b,eloxepine-2-carboxylate mono-hydrate. Arzneim.-Forsch . (1991) 41:1230–6.
   PubMedGoogle Scholar
• KARASAWA A, SHIRAICURA S, HIGO K, KUBO K: Actions of the novel thromboxane A2 receptor antagonist so-dium (e)-11-[2-(5,6-dimethyl-1- benzimidazoly1)-ethylidene[- 6, 11- dihydro dibenz [b, e[o xepine-2-carlboxylate monohydrate on smooth muscle prepara-tions. Arzneim.- Forsch. (1991) 41:1237–41.
   PubMed Web of Science ®Google Scholar
• SHIRAKURA S, KARASAWA A, KUBO K: Protective effectsof the novel thromboxane A2 receptor antagonist so-dium (e)-11-[2-(5,6-dimethy1-1- benzimidazoly1)-ethylidene[-6, 11- dihydro dibenz [b,e[oxepine-2-carbox-ylate monohydrate a :Rinct 9,11-dideoxy-9a,11a-epoxymethano- prostaglandin F2a-induced sudden death in guinea-pigs and rats. Arzrzeim.-Forsch. (1991) 41:1242–5.
   PubMed Web of Science ®Google Scholar
• KAWAKAGE M, SHIRAICURA S, KARASAWA A, TAICEDA M, MIKI I, ISHII, ICUS° K: Beneficial effect of the novel thromboxane A2 receptor antagonist sodium (e)-1142-(5,6-dimethy1-1-benzimidazoly1)-ethylidene]- 6,11-di-hydrodibenz[b,e]oxepine-2-carboxylate monohydrate on collagen- induced coronary ishemia in guinea-pigs. Arzneim.-Forsch. (1991) 41:1246–50.
   PubMedGoogle Scholar
• HIGO K, KARASAWA A, KUBO K: Enhancement of tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by sodium (e)-1112-(5,6-di-methyl- 1-benzimid azoly1)- ethylidene1-6,11-dihy-drodibenz[b,eloxepine-2-carboxylate monohydrate in a canine model of femoral thrombosis. Arzneim.-Forsch. (1991) 41:1251–5.
   PubMed Web of Science ®Google Scholar
• TOMIYAMA T, WAKABAYASHI S, KOSAKAI K, YOKOTA M:Azulene derivatives: new non-prostanoid thrombox-ane A2 receptor antagonists. J. Med. Chem. (1990) 33:2323–26.
   PubMed Web of Science ®Google Scholar
• KOSAKAI K, WAKABAYASHI S, SATOH T, TOMIYAMA A, SATAKE N, SHIBATA S: Pharmacological properties of KT2-962, an azukne derivative, a novel TxA2/P6112 antagonist. FASEB J. (1991) 5:A500.
   Web of Science ®Google Scholar
• MOCHIZUKI S, KOSAKAI K, KOMIYAMA H, WAK-ABAYASHI S, TOMIYAMA A, SATAKE N, SHIBATA: Inhibi-tory effects of KT2-962, a novel non-prostanoid thromboxane A2 receptor antagonist, in various throm-bosis models. FASFB J. (1992) 6:A1318.
   Google Scholar
• NAKAHATA N, SATO K, ABE MT, NAKANISHI: ONO NT-126 Is a potent and selective thromboxane A2 antagonist in human astrocytoma cells. Eur. J. Pharmacol. (1990) 184:233–8.
   PubMed Web of Science ®Google Scholar
• TAKANO S, ISHIMOTO, NAKAHATA N, NAKANISHI H: Thromboxane A2 receptor characterization in human astrocytoma cells and rabbit platelets by a new throm-boxane antagonist, BRION° NT-126. Res. Commun. Chem. Pathol. Pharmacol. (1992) 76:155–70.
   PubMedGoogle Scholar
• SCHENK J, FELLIER H, MITREY Z, SCHMIDT G, SAMHAI3EREM, BREDDIN HK: Effects of a novel selective thrombox-ane receptor antagonist IIN-11500 on platelet function In man. A prospective, randomized phase-1 study. Thromb. Haemostasis (1993) 69:673.
   Google Scholar
• ROALD HE, BARSTAD RM, ENGEN A, KLERULF P, SKIORTEN F, SAKARIASSEN KS: Phase I study-HN-11500-a novel thromboxane receptor antagonist with antitbromlbotic activity in humans with arterial blood flow conditions. 7bromb. Haemostasis (1993) 69:639.
   Web of Science ®Google Scholar
• ROALD HE, BARSTAD RM, ENGEN A, KIERULF P, SKJORTEN F, SAKARIASSEN KS: ELN-11500- a novel thromboxane A2 receptor antagonist with antithrombotic activity in humans at arterial blood flow conditions. Thromb. Haemartasis (1994) 71:103–9.
   PubMed Web of Science ®Google Scholar
• ANTIPLATELET TRIALISTS' COLLABORATION: Collabora- tive overview of randomised trials of antiplatelet ther-apy-l: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various catagories of patients. Br. Med. J. (1994) 308:81–106.
   PubMed Web of Science ®Google Scholar
• Meta-analysis establishing efficacy of aspirin.
   Google Scholar
• ANTIPLATELET TRIALISTS' COLLABORATION: Collabora- tive overview of randomised trials of antiplatelet ther-apy-II: maintenance of vascular graft or arterial patency by antiplatelet therapy. Br. Med. J. (1994) 388:159-68. Meta-analysis establishing efficacy of aspirin.
   Google Scholar
• ANTIPLATFIFT TRIALISTS' COLLABORATION: Collabora-tive overview of randomised trials of antiplatelet ther-apy-III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br. Med. J. (1994) 308:235–46.
   PubMed Web of Science ®Google Scholar
• Meta-analysis establishing efficacy of aspirin.
   Google Scholar